pfe stock today latest news: Pfizer stock soars as earnings smash expectations, and company raises outlook
Pfizer’s stock rises after increasing the profit estimation
According to the report, the company is expected to be between $ 2025 and $ 3,10 for 2025. Pfizer also kept 2025 revenue estimation between $ 61 billion between $ 64 billion, as reported by CNBC.
“As quoted in the CNBC report, Pfizer CFO David Denton said,“ We have relied on our ability to execute strong results against our strategic priorities by increasing our 2025 fixed diluted EPS guide, ”he said.
Read: Plastic Treaty 2025: Will world leaders finally touch on the $ 1.5 trillion health crisis in Geneva?
How does Pfizer address political pressure on drug prices?
The optimistic view of the company comes despite the difficulties of US political pressure, including tariffs and potential pricing reforms defended by US President Donald Trump, according to the US CNBC report. According to the report, the company will reach the third quarter results with a one -time charging accusation for a licensing agreement for cancer treatment outside China.
Pfizer’s Q2 Results Wall Street great surprise
Investors were encouraged by Pfizer’s second quarter performance, which exceeded the expectations of Wall Street, according to Pfizer’s CNBC report. As reported by CNBC, the corrected earnings per share came at 78 cents. According to the CNBC report, income increased by 10% annually to $ 14.65 billion.
Also read: When the July Jobs report draws a terrible picture, 114 companies are planning to dismiss in August – Is You In the List?
Pfizer’s Covid Products Revenue Increase Lead
Behind the growth was Pfizer’s Covid products, including a larger market share and a 96% increase in revenue due to a larger market share and more international contract. According to the CNBC report, the company’s antiviral pill Paxlovid has released powerful sales by 70% increased by the previous year despite less Covid infection worldwide.
In addition to other drugs used to treat heart muscle disease such as Vyndaqel, bladder cancer treatment Padceev and blood thinner Eliquis contributed to the positive sales momentum according to the report. However, according to the CNBC report, the company, which sees that the US prices were lower due to medical reforms and general competition, faced head winds from Ibrance.
Pfizer’s Costs Plans to Increase Snow
The second quarter results come in April after the company increases the cost of reducing costs aimed at helping to get rid of the rapid decrease in COVID business and stock price in the last few years, according to the report of the pharmaceutical company. With the added deductions announced in April, the company is now waiting for about $ 7.7 billion from two separate cost reduction programs by the end of 2027, as reported by the CNBC.
FAQ
What helped Pfizer’s income to grow in this quarter?
Mostly, according to the CNBC report, Covid vaccine and antiviral pill with strong sales from other drugs such as heart and cancer treatments.
What does Pfizer do to reduce costs?
According to the CNBC report, they increased cost -reduction programs and expected to save about $ 7.7 billion by the end of 2027.
